Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine the proportion of patients without
progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are
taking RTA 402.